Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024
Portfolio Pulse from Benzinga Newsdesk
Unicycive Therapeutics announced favorable results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal trial, highlighting its tolerability and safety. The company plans to submit a New Drug Application in Q3 2024.
June 25, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unicycive Therapeutics announced positive results from its pivotal trial for Oxylanthanum Carbonate UNI-OLC-201, demonstrating favorable tolerability and safety. The company plans to submit a New Drug Application in Q3 2024.
The positive trial results and the anticipated New Drug Application submission are likely to boost investor confidence in Unicycive Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100